Axentri 150mg Tablet

Axentri 150mg tablet is a targeted therapy. The medicine works by reducing the viral body from the body. Medicine active ingredient is Maraviroc, present in the 150mg strength. Medicine works by blocking the CCR5 receptor on the surface of immune cells, preventing the HIV from entering these cells from multiplying. Doctor prescribed this medication as the first line therapy to slow the disease progression and support the immune system.

Treat Human immunodeficiency virus (HIV) and Autoimmune deficiency syndrome (AIDS)

Axentri 150mg tablet is an antiviral medication. The medication shows various side effects, some of the symptoms may resolve on their own but some need proper medical procedure to treat. Consult the doctor while experiencing any of these:
● Abnormal vision
● Cataract
● Discomfort in the eye
● Dry eyes
● Depression
● Stomach ulcers
● Tiredness
● Bone problems
● Inflammation in heart muscles
● Inflammation of pancreas
● Glaucoma
● Increased blood sugar levels
● Decreased potassium levels

Axentri 150mg tablet is an oral formulation which should be taken with or without food to avoid stomach upset also taking the medicine at the right time everyday to increase the effectiveness of the treatment. The medication correct dosage and duration is only determined by the healthcare professional. Do not double the dose on the missed one without consultation with a doctor. Strict medical attention is much needed on dosage and duration.

HIV is an antiviral drug that attacks the body's immune system and it can lead to AIDS which is an advanced stage of the infection where the immune system becomes weeks. Axentri 150mg tablet prevent HIV from multiplying in the bod. its active ingredient inhibits viral entry into host CD4 + T cells. By blocking CCR5 co-receptor, the medicine prevents HIV from binding and fusing with the cell membrane, thereby reducing viral replication and slowing disease progression.

• Carter, N. J., & Keating, G. M. (2007). Maraviroc. Drugs, 67(15), 2277-2288.
• Woollard, S. M., & Kanmogne, G. D. (2015). Maraviroc: a review of its use in HIV infection and beyond. Drug design, development and therapy, 5447-5468.
• MacArthur, R. D., & Novak, R. M. (2008). Maraviroc: the first of a new class of antiretroviral agents. Clinical Infectious Diseases, 47(2), 236-241.
• Abel, S., Back, D. J., & Vourvahis, M. (2009). Maraviroc: pharmacokinetics and drug interactions. Antiviral therapy, 14(5), 607-618.
• Gulick, R. M., Lalezari, J., Goodrich, J., Clumeck, N., DeJesus, E., Horban, A., ... & Mayer, H. (2008). Maraviroc for previously treated patients with R5 HIV-1 infection. New England Journal of Medicine, 359(14), 1429-1441.